HBsAg Clearance and Its Implications

Introduction to HBsAg Clearance

The American Association for the Study of Liver Diseases recommends that HBsAg clearance is a desirable outcome, occurring at approximately 0.5% per year in chronic carriers, representing "resolved hepatitis B" with sustained loss of HBsAg, undetectable HBV DNA, and absence of active viral infection 1, 2

Approximately 0.5% of HBsAg carriers clear the antigen yearly, with most patients subsequently developing anti-HBs antibodies 3, 4
Clearance typically follows years of chronic infection, often after HBeAg seroconversion, with older age and prior HBeAg clearance being predictors of impending HBsAg clearance 3, 5
Initial HBeAg clearance occurs at 8-12% per year in adults with elevated ALT, after which 67-80% of carriers enter the "inactive carrier state" with low/undetectable HBV DNA and normal ALT 3, 5

From the inactive carrier state, approximately 0.5% annually progress to complete HBsAg clearance, with the European Association for the Study of the Liver recommending monitoring for HBV DNA by PCR, as low-level viremia may persist 3, 4

The American Association for the Study of Liver Diseases notes that HBsAg negativity does NOT equal complete viral eradication, with low levels of HBV DNA remaining detectable by PCR in up to 50% of patients after HBsAg disappearance, and covalently closed circular DNA (cccDNA) persisting in hepatocytes even after HBsAg clearance 3, 6
Patients remain at risk for HBV reactivation if subsequently immunosuppressed, with the Clinical and Molecular Hepatology society recommending testing HBV DNA even in HBsAg-negative/anti-HBc-positive patients before any immunosuppressive therapy 6, 7

Hepatocellular carcinoma can develop even after HBsAg clearance, particularly if HBV DNA persists, with the American Association for the Study of Liver Diseases recommending screen for hepatocellular carcinoma if prior cirrhosis or advanced fibrosis existed 4
The risk of hepatic decompensation decreases but is not eliminated, with the European Association for the Study of the Liver recommending continued surveillance and monitoring for HBV DNA by PCR 4, 7